Showing results (1-10 of 384) with videos related to
Sort By:
Pageof 39
Current Pharmaceutical Design|August 20, 2009
Fcgamma receptor 1 (CD64), a target beyond cancerT Thepen, M Huhn, G Melmer, et al.The British Journal of Dermatology|April 30, 2010
Recombinant, ETA'-based CD64 immunotoxins: improved efficacy by increased valency, both in vitro and in vivo in a chronic cutaneous inflammation model in human CD64 transgenic miceT Ribbert, T Thepen, M K Tur, et al.Biotechniques|March 10, 2001
Selection of scFv phages on intact cells under low pH conditions leads to a significant loss of insert-free phagesM K Tur, M Huhn, S Sasse, et al.Blood Cancer Journal|March 26, 2013
Efficacy of an adapted granzyme B-based anti-CD30 cytolytic fusion protein against PI-9-positive classical Hodgkin lymphoma cells in a murine modelS Schiffer, H P Hansen, G Hehmann-Titt, et al.British Journal of Cancer|August 15, 2013
Microtubule-associated protein tau facilitates the targeted killing of proliferating cancer cells in vitro and in a xenograft mouse tumour model in vivoD Hristodorov, R Mladenov, A Pardo, et al.Cancer Research|December 26, 2001
Human angiogenin fused to human CD30 ligand (Ang-CD30L) exhibits specific cytotoxicity against CD30-positive lymphomaM Huhn, S Sasse, M K Tur, et al.International Journal of Molecular Medicine|September 18, 2004
Construction of phage display libraries from reactive lymph nodes of breast carcinoma patients and selection for specifically binding human single chain Fv on cell linesA Rothe, A Klimka, M K Tur, et al.International Journal of Molecular Medicine|October 18, 2001
An anti-GD2 single chain Fv selected by phage display and fused to Pseudomonas exotoxin A develops specific cytotoxic activity against neuroblastoma derived cell linesM K Tur, S Sasse, M Stöcker, et al.Journal of Molecular Biology|September 1, 2000
Combining phage display and screening of cDNA expression libraries: a new approach for identifying the target antigen of an scFv preselected by phage displayS Barth, U Weidenmüller, M K Tur, et al.Cytokines, Cellular & Molecular Therapy|October 9, 1999
CD30L-ETA': a new recombinant immunotoxin based on the CD30 ligand for possible use against human lymphomaS Barth, B Matthey, M Huhn, et al.Pageof 39